Kyverna Therapeutics, Inc. Basic Shares Outstanding (Weighted Average)
Kyverna Therapeutics, Inc. (KYTX) reported Basic Shares Outstanding (Weighted Average) of 60.90 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-11
- Kyverna Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 60.90M shares, a 40.88% increase year-over-year.
- Kyverna Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 60.43M shares, a 39.84% increase year-over-year.
- Kyverna Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 47.19M shares, a 9.15% increase year-over-year.
- Kyverna Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 43.42M shares, a 0.60% increase year-over-year.
- Kyverna Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 44.26M shares, a 15.46% increase from fiscal 2024.
- Kyverna Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 38.33M shares, a 5590.81% increase from fiscal 2023.
- Kyverna Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 673.62K shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 60.90M shares 10-Q · filed 2026-08-11 | 60.67M shares 10-Q · filed 2026-08-11 | 56.17M shares derived: average of 3 quarters · filed 2026-08-11 | 52.98M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 60.43M shares 10-Q · filed 2026-05-12 | 53.81M shares derived: average of 2 quarters · filed 2026-05-12 | 50.35M shares derived: average of 3 quarters · filed 2026-05-12 | 48.57M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | 47.19M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 45.30M shares derived: average of 2 quarters · filed 2026-03-26 | 44.61M shares derived: average of 3 quarters · filed 2026-08-11 | 44.26M shares 10-K · filed 2026-03-26 |
| 2025-09-30 | 43.42M shares 10-Q · filed 2025-11-12 | 43.32M shares derived: average of 2 quarters · filed 2026-08-11 | 43.28M shares 10-Q · filed 2025-11-12 | 43.27M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | 43.23M shares 10-Q · filed 2026-08-11 | 43.22M shares 10-Q · filed 2026-08-11 | 43.22M shares derived: average of 3 quarters · filed 2026-08-11 | 43.21M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | 43.22M shares 10-Q · filed 2026-05-12 | 43.22M shares derived: average of 2 quarters · filed 2026-05-12 | 43.20M shares derived: average of 3 quarters · filed 2026-05-12 | 43.18M shares derived: average of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | 43.23M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 43.19M shares derived: average of 2 quarters · filed 2026-03-26 | 43.17M shares derived: average of 3 quarters · filed 2026-03-26 | 38.33M shares 10-K · filed 2026-03-26 |
| 2024-09-30 | 43.16M shares 10-Q · filed 2025-11-12 | 43.14M shares derived: average of 2 quarters · filed 2025-11-12 | 36.70M shares 10-Q · filed 2025-11-12 | 27.71M shares derived: average of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | 43.13M shares 10-Q · filed 2025-08-12 | 33.44M shares 10-Q · filed 2025-08-12 | 22.56M shares derived: average of 3 quarters · filed 2025-08-12 | 17.09M shares derived: average of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | 23.75M shares 10-Q · filed 2025-05-13 | 12.28M shares derived: average of 2 quarters · filed 2025-05-13 | 8.41M shares derived: average of 3 quarters · filed 2025-05-13 | 6.46M shares derived: average of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | 796.62K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 730.64K shares derived: average of 2 quarters · filed 2025-03-27 | 696.29K shares derived: average of 3 quarters · filed 2025-03-27 | 673.62K shares 10-K · filed 2025-03-27 |
| 2023-09-30 | 664.66K shares 10-Q · filed 2024-11-13 | 646.12K shares derived: average of 2 quarters · filed 2024-11-13 | 632.62K shares 10-Q · filed 2024-11-13 | |
| 2023-06-30 | 627.59K shares 10-Q · filed 2024-08-12 | 599.92K shares 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | 921.26K shares 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |